Fig. 4From: Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisChange from baseline in double product. ABPM ambulatory blood pressure monitoring, bpm beats per minute, CANA canagliflozin, CI confidence interval, LS least squares, PBO placebo, SE standard errorBack to article page